Revival research Institute, LLC

Troy, Michigan 48312

10 studies enrolling now · 40 studies all time

What they study most

AD, Acne Inversa, Alopecia Areata, Atopic Dermatitis, Atopic Dermatitis, Unspecified, Atopic Eczema, Atopic Hand and Foot Dermatitis, Atoptic Dermatitis, Chronic Cutaneous Lupus Erythematosus, Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Cold Urticaria

Studies at this site

• A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo — Recruiting now
• A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Recruiting now
• A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) — Recruiting now
• A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) — Recruiting now
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Recruiting now
• Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis — Recruiting now
• FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Recruiting now
• A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. — Recruiting now
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Recruiting now
• A Study of Barzolvolimab in Patients With Prurigo Nodularis — Running, not enrolling
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — Enrolling by invitation
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — Running, not enrolling
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis — Stopped early
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) — Completed
• A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis — Running, not enrolling
• A Study of DS-7011a in Patients With Systemic Lupus Erythematosus — Completed
• Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial — Completed
• A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Running, not enrolling
• Phase 2b Study of EVO756 in Adults With Atopic Dermatitis — Running, not enrolling
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis — Running, not enrolling
• A Study of Barzolvolimab in Patients With Atopic Dermatitis — Running, not enrolling
• To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis — Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis — Completed
• A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis — Stopped early
• A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) — Stopped early
• A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 — Completed
• Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis — Completed
• A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection — Stopped early
• Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) — Completed
• A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis — Completed
• Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea — Completed
• A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis — Stopped early
• A Study of CDX-0159 in Patients With Prurigo Nodularis — Completed
• A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa — Completed
• A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa — Completed
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy — Completed
• Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis — Status unconfirmed